CL2024000890A1 - Polipéptidos de unión a antígeno, complejos de polipéptidos de unión a antígeno y métodos de uso de los mismos en el vih - Google Patents
Polipéptidos de unión a antígeno, complejos de polipéptidos de unión a antígeno y métodos de uso de los mismos en el vihInfo
- Publication number
- CL2024000890A1 CL2024000890A1 CL2024000890A CL2024000890A CL2024000890A1 CL 2024000890 A1 CL2024000890 A1 CL 2024000890A1 CL 2024000890 A CL2024000890 A CL 2024000890A CL 2024000890 A CL2024000890 A CL 2024000890A CL 2024000890 A1 CL2024000890 A1 CL 2024000890A1
- Authority
- CL
- Chile
- Prior art keywords
- antigen binding
- polypeptide complexes
- polypeptides
- hiv
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/112—Retroviridae (F), e.g. leukemia viruses
- C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/112—Retroviridae (F), e.g. leukemia viruses
- C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
- C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- AIDS & HIV (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163249722P | 2021-09-29 | 2021-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024000890A1 true CL2024000890A1 (es) | 2024-10-11 |
Family
ID=85783606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000890A CL2024000890A1 (es) | 2021-09-29 | 2024-03-27 | Polipéptidos de unión a antígeno, complejos de polipéptidos de unión a antígeno y métodos de uso de los mismos en el vih |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250197481A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4408892A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024537827A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240099226A9 (cg-RX-API-DMAC7.html) |
| CN (1) | CN118660907A (cg-RX-API-DMAC7.html) |
| AR (1) | AR127176A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022357501A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3232365A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024000890A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL311762A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024003804A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202325744A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023056315A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202330594A (zh) | 2021-09-29 | 2023-08-01 | 美商莫德斯醫療公司 | 抗原結合多肽、抗原結合多肽複合物及其使用方法 |
| CN116574748B (zh) * | 2023-07-10 | 2023-09-12 | 昆明医科大学 | 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法 |
| WO2025162460A1 (zh) * | 2024-02-04 | 2025-08-07 | 南通壹宸生物医药科技有限公司 | 一种轭合化合物及其制备和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI622597B (zh) * | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| JP6407726B2 (ja) * | 2012-03-01 | 2018-10-24 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH | 長寿命ポリペプチド結合分子 |
| US9458244B2 (en) * | 2012-12-28 | 2016-10-04 | Abbvie Inc. | Single chain multivalent binding protein compositions and methods |
| ES2894304T3 (es) * | 2015-10-25 | 2022-02-14 | Sanofi Sa | Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH |
| EP3443006B1 (en) * | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| WO2018075564A1 (en) * | 2016-10-17 | 2018-04-26 | University Of Maryland, College Park | Multispecific antibodies targeting human immunodeficiency virus and methods of using the same |
| US12365722B2 (en) * | 2018-10-19 | 2025-07-22 | University Of Maryland, College Park | Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope |
| EP4578507A3 (en) * | 2018-11-01 | 2025-11-12 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| TW202104274A (zh) * | 2019-04-09 | 2021-02-01 | 法商賽諾菲公司 | 用於治療hiv感染之三特異性及/或三價結合蛋白 |
| EP4397748A4 (en) * | 2021-08-30 | 2025-09-17 | Kanglin Biotechnology Hangzhou Co Ltd | GENE SEQUENCE CONSTRUCTION FOR GENE THERAPY AGAINST HIV INFECTION |
-
2022
- 2022-09-28 EP EP22877542.5A patent/EP4408892A4/en active Pending
- 2022-09-28 WO PCT/US2022/077203 patent/WO2023056315A1/en not_active Ceased
- 2022-09-28 IL IL311762A patent/IL311762A/en unknown
- 2022-09-28 KR KR1020247014156A patent/KR20240099226A9/ko active Pending
- 2022-09-28 CA CA3232365A patent/CA3232365A1/en active Pending
- 2022-09-28 AR ARP220102616A patent/AR127176A1/es unknown
- 2022-09-28 US US18/696,493 patent/US20250197481A1/en active Pending
- 2022-09-28 TW TW111136760A patent/TW202325744A/zh unknown
- 2022-09-28 MX MX2024003804A patent/MX2024003804A/es unknown
- 2022-09-28 CN CN202280078694.3A patent/CN118660907A/zh active Pending
- 2022-09-28 AU AU2022357501A patent/AU2022357501A1/en active Pending
- 2022-09-28 JP JP2024519822A patent/JP2024537827A/ja active Pending
-
2024
- 2024-03-27 CL CL2024000890A patent/CL2024000890A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023056315A1 (en) | 2023-04-06 |
| CN118660907A (zh) | 2024-09-17 |
| EP4408892A4 (en) | 2025-11-19 |
| US20250197481A1 (en) | 2025-06-19 |
| EP4408892A1 (en) | 2024-08-07 |
| JP2024537827A (ja) | 2024-10-16 |
| KR20240099226A9 (ko) | 2025-12-10 |
| MX2024003804A (es) | 2024-06-11 |
| TW202325744A (zh) | 2023-07-01 |
| IL311762A (en) | 2024-05-01 |
| CA3232365A1 (en) | 2023-04-06 |
| AR127176A1 (es) | 2023-12-27 |
| KR20240099226A (ko) | 2024-06-28 |
| AU2022357501A1 (en) | 2024-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024000907A1 (es) | Polipéptidos de unión a antígeno, complejos de polipéptidos de unión a antígeno y métodos de uso de los mismos | |
| CL2024001850A1 (es) | Complejos polipeptídicos de unión a antígeno activados condicionalmente y métodos de uso de los mismos. | |
| PE20220495A1 (es) | Receptores antigenicos quimericos y agentes de union dirigidos a dll3 | |
| EA202192103A1 (ru) | Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1) | |
| AR111362A1 (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno | |
| MX2024006968A (es) | Anticuerpos cdh17 y metodos de tratamiento del cancer. | |
| MX2024003804A (es) | Polipeptidos de union a antigeno, complejos de polipeptidos de union a antigeno y metodos de uso de los mismos en el vih. | |
| PE20201149A1 (es) | Anticuerpos de union a hla-a2/wt1 | |
| BR112017014805A2 (pt) | anticorpos anti-cd3, anticorpos anti-cd123 e anticorpos biespecíficos que se ligam especificamente a cd3 e/ou cd123 | |
| CL2021000942A1 (es) | Anticuerpos anti-npr1 y usos relacionados. | |
| PY1888702A (es) | Anticuerpos anti-cd38 y métodos de uso | |
| BR112017003194A2 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo, composição, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, vacina, vaso ou dispositivo de injeção, e, métodos para antagonizar lag3 em um paciente humano que necessita do mesmo, para tratamento de um câncer em um indivíduo para administrar o anticorpo, o fragmento, a composição, o polipeptídeo, a vacina, o vetor ou o polinucleotídeo de ligação ao antígeno a um indivíduo, para produção de um anticorpo ou de um fragmento de ligação ao antígeno do mesmo ou polipeptídeo e para detectar a presença de um peptídeo lag3 ou de um fragmento do mesmo em uma amostra. | |
| PE20240761A1 (es) | Proteinas de union a psma y usos de estas | |
| CL2016001134A1 (es) | Celula t o celula asesina natural (nk) que expresa dos receptores de antigeno quimerico (car), donde un car comprende un endodominio activador y el otro un dominio inhibitorio de proteina tirosina fosfatasa que contiene el dominio src (sh2); acido nucleico; vector; metodo de produccion; composicion; uso para preparar medicamento. | |
| AR121019A2 (es) | Péptido, ácido nucleico que lo codifica, anticuerpo, linfocito t, receptor de linfocito t, aptámero, célula hospedadora recombinante, composición farmacéutica y equipo | |
| AR128013A1 (es) | Complejos polipeptídicos de unión a antígeno que contienen dominios extracelulares de ligandos tnfsf | |
| MX2021012488A (es) | Receptores de antigeno quimerico del receptor 1 anti-folato humanizado y usos de los mismos. | |
| MX2024015643A (es) | Polipéptidos de unión al antígeno contra el coronavirus 2 del síndrome respiratorio agudo grave (anti-sars-cov-2), complejos de polipéptidos y métodos de uso de estos | |
| AR127177A1 (es) | Polipéptidos de unión a antígeno, complejos de polipéptidos de unión a antígeno y métodos de uso de los mismos | |
| MX2024006969A (es) | Anticuerpos dlk1 y metodos de tratamiento del cancer. | |
| AR121810A2 (es) | Péptido, vector de expresión, célula huésped, linfocito t activado, anticuerpo, receptor de células t, composición farmacéutica, kit y métodos relacionados | |
| PE20252241A1 (es) | Anticuerpos anti-pdl1/vegf y metodos de uso | |
| AR121632A2 (es) | Péptidos y combinaciones de péptidos capaces de unirse a mhc e inducir reactividad cruzada de linfocitos t | |
| CO2024000677A2 (es) | Proteínas de unión a antígenos que se unen específicamente a ct45 | |
| AR113757A1 (es) | Anticuerpos anti-cd38 y métodos de uso |